ClinicalTrials.gg
Sign In

Thyroid Cancer, Papillary clinical trials

The registry lists 186 studies for Thyroid Cancer, Papillary across more than 10 countries. 51 are recruiting or about to start. 120 of them are mainly about Thyroid Cancer, Papillary (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Thyroid Cancer, Papillary studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
83
Recruiting
33
Status unknown
20
Not yet recruiting
17
Active, not recruiting
17
Terminated
13

Phase

Phase 2
52
Phase 1
23
Phase 3
8
Phase 4
2
Early Phase 1
1

Where

United States
75
China
40
Italy
17
Canada
15
Korea, Republic of
15
Spain
11

Who runs them

National Cancer Institute (NCI) (18) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (6) · University Health Network, Toronto (4) · Hoffmann-La Roche (4) · M.D. Anderson Cancer Center (4) · Chinese PLA General Hospital (4) · Massachusetts General Hospital (4) · Fujian Medical University (4)

What is being tested here

Drugs under test in Thyroid Cancer, Papillary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Vemurafenib214
Cobimetinib212
Selpercatinib104
Dabrafenib113
Trametinib112
Thyroxine102
Sacituzumab tirumotecan101
Mitoxantrone101
Zanzalintinib101
Iodine I-131101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Angiogenesis inhibitors 4 · Immune checkpoint inhibitors 3

Coming up

6phase 3 studies under way
17studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 33 Thyroid Cancer, Papillary studies recruiting now, 20 (61%) set no upper age limit and 8 (24%) stop at 75 or younger. 15 (45%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (9%) take healthy volunteers.

Recruiting studies that take each age, of 33
AgeWomenMen
1010 (30%)10 (30%)
1833 (100%)33 (100%)
3033 (100%)33 (100%)
4033 (100%)33 (100%)
5033 (100%)33 (100%)
6532 (97%)32 (97%)
7526 (79%)26 (79%)
8522 (67%)22 (67%)

Across all 186 studies, recruiting or not: 18% stop at 75 or younger and 8% at 65; 24% take children; 1% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Thyroid Cancer, Papillary studies take

Of 26 interventional studies with no phase under Thyroid Cancer, Papillary, half reached primary completion within 36 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase36 mo23–71 · 26 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered2

Studies

Recruiting first, then most recently updated. Showing 50 of 186. Browse all 186 → or search them.